Other equities analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $6.50 target price (up previously from $1.00) on shares of Cesca Therapeutics in a research note on Wednesday, August 14th. Zacks Investment Research upgraded shares of Cesca Therapeutics from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a research note on Tuesday, August 20th.
KOOL traded down $0.26 during midday trading on Tuesday, hitting $6.37. 216,400 shares of the company traded hands, compared to its average volume of 113,917. The company has a quick ratio of 0.91, a current ratio of 1.52 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $15.44 million, a PE ratio of -1.77 and a beta of 0.93. The company’s 50-day moving average is $4.07 and its 200 day moving average is $2.17. Cesca Therapeutics has a 52 week low of $2.10 and a 52 week high of $7.00.
About Cesca Therapeutics
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
Featured Story: What are the advantages of the Stochastic Momentum Index?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.